Impact on breast cancer diagnosis in a multidisciplinary unit after the incorporation of mammography digitalization and computer-aided detection systems.

OBJECTIVE: The purpose of this article is to evaluate the impact on the diagnosis of breast cancer of implementing full-field digital mammography (FFDM) in a multidisciplinary breast pathology unit and, 1 year later, the addition of a computer-aided detection (CAD) system. MATERIALS AND METHODS: A total of 13,453 mammograms performed between January and July of the years 2004, 2006, and 2007 were retrospectively reviewed using conventional mammography, digital mammography, and digital mammography plus CAD techniques. Mammograms were classified into two subsets: screening and diagnosis. Variables analyzed included cancer detection rate, rate of in situ carcinoma, tumor size at detection, biopsy rate, and positive predictive value of biopsy. RESULTS: FFDM increased the cancer detection rate, albeit not statistically significantly. The detection rate of in situ carcinoma increased significantly using FFDM plus CAD compared with conventional technique (36.8% vs 6.7%; p = 0.05 without Bonferroni statistical correction) for the screening dataset. Relative to conventional mammography, tumor size at detection decreased with digital mammography (T1, 61.5% vs 88%; p = 0.018) and with digital mammography plus CAD (T1, 79.7%; p = 0.03 without Bonferroni statistical correction). Biopsy rates in the general population increased significantly using CAD (10.6/1000 for conventional mammography, 14.7/1000 for digital mammography, and 17.9/1000 for digital mammography plus CAD; p = 0.02). The positive predictive value of biopsy decreased slightly, but not significantly, for both subsets. CONCLUSION: The incorporation of new techniques has improved the performance of the breast unit by increasing the overall detection rates and earlier detection (smaller tumors), both leading to an increase in interventionism.

Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients.

A precise description of clinical features at presentation and analysis of clinical and biologic prognostic factors in splenic marginal zone lymphoma (SMZL) are still lacking. Here we describe the clinical and biologic features of a series of 60 SMZL patients diagnosed after splenectomy. Analysis for overall survival (OS), failure-free survival (FFS), and the probability of obtaining a response was performed using univariate and multivariate tests. The median age of the patient was 63 years (range, 35-84 years). Performance status according to the Eastern Cooperative Oncology Group (ECOG scale) was 0 = 16%, 1 = 58%, and 2 = 25%. Of the 60 patients, 53 (86.6%) were at Ann Arbor stage IV. All 60 patients received splenectomies, 29 of 60 also received chemotherapy, and 2 received spleen radiotherapy. A complete response (CR) was achieved by 38.3% of patients, and a partial response (PR) was achieved by 55%. Mean OS of the series was 103 months (range, 2-164 months); mean FFS was 40 months (range, 3-164 months). At 5 years from diagnosis, 39 patients (65%) were alive. Patients dying from the disease had a relatively aggressive clinical course, with a short survival (17.5 months [range, 2-72 months]). Significant prognostic factors in multivariate analysis were (1) (for OS and FFS) lack of response to therapy (CR versus noncomplete response [nCR]) and involvement of nonhematopoietic sites, and (2) (for the probability of obtaining CR) bone marrow involvement. Chemotherapy did not influence OS or FFS. p53 overexpression predicted a shorter OS in the univariate analysis. These data confirm the relative indolence of this disease, indicating the existence of a subset of more aggressive cases, which should stimulate the search for predictive biologic factors and alternative therapies.